Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer

Experimental and Therapeutic Medicine

Volumn 4, Issue 6, 2012, Pages 1010-1016

  Hu, Qiong ^a   Li, Xuefei ^b   Su, Chunxia ^a   Chen, Xiaoxia ^a   Gao, Guanghui ^a   Zhang, Jie ^b   Zhao, Yinmin ^b   Li, Jiayu ^b   Zhou, Caicun ^a,b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

Non small cell lung cancer; Pemetrexed; Polymorphism; Thymidylate synthase

Indexed keywords

CYANOCOBALAMIN; FLUMETASONE; FOLIC ACID; PEMETREXED; RANITIDINE; THYMIDYLATE SYNTHASE;

5' UNTRANSLATED REGION; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; CORRELATION COEFFICIENT; DNA POLYMORPHISM; DRUG EFFICACY; FEMALE; GENE DELETION; GENE INSERTION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; SEX DIFFERENCE; SHORT TANDEM REPEAT; SMOKING; TREATMENT OUTCOME; TREATMENT RESPONSE; VARIABLE NUMBER OF TANDEM REPEAT;

EID: 84867272757     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.730     Document Type: Article

References (23)

1. Rahman L, Voeller D, Rahman M, et al: Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 5: 341-351, 2004.
2. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551, 2008.
3. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-smallcell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597, 2004.
4. Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase III study. Lancet 374: 1432-1440, 2009.
5. Scagliotti G, Brodowicz T, Shepherd FA, et al: Treatment-byhistology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 6: 64-70, 2011.
6. Tanaka F, Wada H, Fukui Y and Fukushima M: Thymidylate synthase gene expression in primary lung cancer patients: a large-scale study in Japanese population. Ann Oncol 22: 1791-1797, 2011.
7. Kaira K, Ohde Y, Nakagawa K, Okumura T, et al: Thymidylate synthase expression is closely associated with outcomes in patients with pulmonary adenocarcinoma. Med Oncol 29: 1663-1672, 2012
8. Sun JM, Han J, Ahn JS, Park K and Ahn MJ: Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based treatment. J Thorac Oncol 6: 1392-1399, 2011.
9. De Bock CE, Garg MB, Scott N, Sakoff JA, Scorgie FE, Ackland SP and Lincz LF: Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo. Pharmacogenomics J 11: 307-314, 2011.
10. Mandola MV, Stoehlmacher J, Zhang W, et al: A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14: 319-327, 2004.
11. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ and Ladner RD: Ladner, a novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63: 2898-2904, 2003.
12. Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W and Lenz HJ: Thymidylate synthase gene variations: predictive and prognostic markers. Mol Cancer Ther 8: 1000-1007, 2009.
13. Shitara K, Muro K, Ito S, et al: Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer. Cancer Epidemiol Biomarkers Prev 19: 1311-1319, 2010.
14. Kumar K, Vamsy M and Jamil K: Thymidylate synthase gene polymorphisms effecting 5-FU response in breast cancer patients. Cancer Biomark 6: 83-93, 2010.
15. Takehara A, Kawakami K, Ohta N, Oyama K, Ota Y, Oda M and Watanabe G: Prognostic significance of the polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase gene in lung cancer. Anticancer Res 25: 4455-4461, 2005.
16. Sobin LH, Gospodarowicz MK and Wittekind CH (eds): International Union Against Cancer (UICC) TNM Classification of Malignant Tumours. 7th edition. Wiley-Blackwell, Oxford, pp 1-256, 2009.
17. th edition. Springer-Verlag, New York, pp 1-195, 2009.
18. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
19. Lu JW, Gao CM, Wu JZ, Cao HX, Tajima K and Feng JF: Polymorphism in the 3'-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy. J Hum Genet. 51: 155-160, 2006.
20. Ettinger DS, Akerley W, Borghaei H, et al: NCCN Clinical Practice Guidelines in Oncology. version 2.2012. National Comprehensive Cancer Network, Fort Washington, PA, pp1-112, 2011. Available at www.nccn.com.
21. Huang ZH, Hua D and Li LH: The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population. Cancer Chemother Pharmacol 63: 911-918, 2009.
22. Giovannetti E, Backus HH, Wouters D, et al: Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 96: 769-775, 2007.
23. Gorlick R, Metzger R, Danenberg KD, et al: Higher levels of thymidylate synthase gene expression are in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J Clin Oncol 16: 1465-1469, 1998.